/
FFTGX
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $253.3M | $233.2M | $204.3M | $150.6M | $111.8M | $107.5M | $72.9M | $18.4M |
| Cost of revenue | $65.2M | $65.4M | $71.2M | $80.7M | $77.9M | $80.3M | $65.7M | $27.4M |
| Gross profit | $188.1M | $167.9M | $133.2M | $69.9M | $33.9M | $27.2M | $7.2M | −$9.0M |
| Gross margin | 74.3% | 72.0% | 65.2% | 46.4% | 30.3% | 25.3% | 9.8% | -48.8% |
| R&D | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating income | −$6.7M | −$122.4M | −$128.6M | −$73.8M | −$91.0M | −$66.0M | −$81.6M | −$69.4M |
| EBITDA | $169.7M | $139.1M | $97.3M | $30.3M | $3.2M | −$14.6M | −$40.3M | −$54.8M |
| Net income | −$51.6M | −$74.0M | −$78.4M | −$64.3M | −$109.9M | −$33.0M | −$78.8M | −$159.8M |
| Net margin | -20.4% | -31.7% | -38.4% | -42.7% | -98.3% | -30.8% | -108.2% | -867.5% |
| EPS (diluted) | -1.64 | -2.19 | -2.20 | -1.77 | -2.87 | -0.78 | -1.59 | -2.85 |
Annual figures · source: Financial Modeling Prep
Peer comparison
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| FFTGXSalient Tactical Growth Fund Investor Class | $25.52 | +0.24% | $243M | — |
| BIPIXProFunds Biotechnology UltraSector Fund Investor Class | $96.31 | -0.10% | $375M | — |
| BTMFXBoston Trust Midcap Fund | $23.97 | +0.17% | $169M | — |
| CRAAXColumbia Adaptive Risk Allocation Fund A | $11.46 | -0.35% | $249M | — |
| ETGIXEaton Vance Greater India A |
Held by traders on TradeandTell
No one on the platform currently holds FFTGX.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in FFTGX as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded FFTGX yet.